Zenotech Laboratories

Zenotech Laboratories OCF/Debt

The Operating Cash Flow to Debt Ratio of Zenotech Laboratories (532039.BO) as of Nov 1, 2026 is 294.46 %. In the previous year, Operating Cash Flow to Debt Ratio was 27.79 % — a change of 959.46% (higher).

OCF/Debt

294.46 %

YoY

959.46%

Last updated:

Operating Cash Flow to Debt Ratio of Zenotech Laboratories is 2022 294.46 % . Operating Cash Flow to Debt Ratio of Zenotech Laboratories was 2021 27.79 % . It decreases by 959.46% higher compared to the previous year.

The Zenotech Laboratories OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2014
-35.10 INR
Jan 1, 2015
-14.19 INR
Jan 1, 2016
-9.37 INR
Jan 1, 2017
3.20 INR
Jan 1, 2019
-69.38 INR
Jan 1, 2020
60.99 INR
Jan 1, 2021
27.79 INR
Jan 1, 2022
294.46 INR
The Zenotech Laboratories OCF/Debt history
YEAROCF/DebtYoY
294.46 %+959.46%
27.79 %-54.43%
60.99 %-187.91%
-69.38 %-2,270.51%
3.20 %-134.11%
-9.37 %-33.97%
-14.19 %-59.56%
-35.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd manufactures and markets pharmaceutical products, specializing in oncology, biotechnology, and general injectables. The company operates from a manufacturing facility in Turkapally village, Shamirpet Mandal, Telangana, producing specialty generic injectables for the pharmaceutical sector. Its products are sold to healthcare providers and distributors within the pharmaceutical industry, targeting markets that require specialized injectable solutions. The firm's business model focuses on the production and distribution of generic injectables, leveraging its facility in Telangana to serve both domestic and international markets. By concentrating on oncology and biotechnology injectables, Zenotech addresses specific medical needs, generating revenue through the sale of these high-demand pharmaceutical products to hospitals, clinics, and pharmaceutical distributors. Zenotech Laboratories Ltd's revenue streams come from the sale of its specialty generic injectables, including oncology and biotechnology products, to healthcare institutions and distribution networks. The company's manufacturing capabilities in Telangana support its role as a supplier in the pharmaceutical supply chain, with a focus on injectable formulations that cater to critical healthcare applications. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

Operating Cash Flow to Debt Ratio of Zenotech Laboratories is 294.46 % in 2022.

Operating Cash Flow to Debt Ratio of Zenotech Laboratories changed from 27.79 % to 294.46 %, representing a 959.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Zenotech Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Zenotech Laboratories

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Zenotech Laboratories